| Item Type | Name |
|
Concept
|
Liver
|
|
Concept
|
Liver Cirrhosis
|
|
Concept
|
Liver Cirrhosis, Alcoholic
|
|
Concept
|
Liver Diseases
|
|
Concept
|
Liver Function Tests
|
|
Concept
|
Liver Neoplasms
|
|
Concept
|
Liver Transplantation
|
|
Concept
|
Non-alcoholic Fatty Liver Disease
|
|
Academic Article
|
Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study.
|
|
Academic Article
|
Genomic profiling of combined hepatocellular-cholangiocarcinoma reveals similar genetics to hepatocellular carcinoma.
|
|
Academic Article
|
Can we cure cholangiocarcinoma with neoadjuvant chemoradiation and liver transplantation? Time for a multicenter trial.
|
|
Academic Article
|
The evolving role of combination systemic therapies in hepatocellular carcinoma.
|
|
Academic Article
|
Hepatocellular Carcinoma - Origins and Outcomes.
|
|
Academic Article
|
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma.
|
|
Academic Article
|
Novel therapeutics in hepatocellular carcinoma: how can we make progress?
|
|
Academic Article
|
Immunotherapy in hepatocellular carcinoma: the complex interface between inflammation, fibrosis, and the immune response.
|
|
Academic Article
|
Brivanib and FOLFOX in hepatocellular carcinoma: finding the common themes among negative trials.
|
|
Academic Article
|
Novel transforming growth factor beta receptor I kinase inhibitor galunisertib (LY2157299) in advanced hepatocellular carcinoma.
|
|
Academic Article
|
Cabozantinib in combination with atezolizumab versus sorafenib in treatment-naive advanced hepatocellular carcinoma: COSMIC-312 Phase III study design.
|
|
Academic Article
|
Comparative Efficacy of Cabozantinib and Regorafenib for Advanced Hepatocellular Carcinoma.
|
|
Academic Article
|
Biomarkers and overall survival in patients with advanced hepatocellular carcinoma treated with TGF-?RI inhibitor galunisertib.
|
|
Academic Article
|
Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial.
|
|
Academic Article
|
Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial.
|
|
Academic Article
|
Nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh class B cirrhosis: Safety and clinical outcomes in a retrospective case series.
|
|
Academic Article
|
Adjuvant sorafenib for liver cancer: wrong stage, wrong dose.
|
|
Academic Article
|
Serum Alpha-fetoprotein Levels and Clinical Outcomes in the Phase III CELESTIAL Study of Cabozantinib versus Placebo in Patients with Advanced Hepatocellular Carcinoma.
|
|
Academic Article
|
Molecular Profiling of Hepatocellular Carcinoma Using Circulating Cell-Free DNA.
|
|
Academic Article
|
Phase II Trial of the Combination of Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma with Tumor Mutation Profiling.
|
|
Academic Article
|
Sorafenib in hepatocellular carcinoma: separating the hype from the hope.
|
|
Academic Article
|
Heterogeneous Uptake of 18F-FDG and 68Ga-PSMA-11 in Hepatocellular Carcinoma.
|
|
Academic Article
|
Emerging Role for Systemic Therapy in Earlier Stages of HCC.
|
|
Academic Article
|
Cases of spontaneous tumor regression in hepatobiliary cancers: implications for immunotherapy?
|
|
Academic Article
|
Atezolizumab plus Bevacizumab - A Landmark in Liver Cancer.
|
|
Academic Article
|
Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma.
|
|
Academic Article
|
Phase 1b study of galunisertib and ramucirumab in patients with advanced hepatocellular carcinoma.
|
|
Academic Article
|
Circulating tumor cells in hepatocellular carcinoma: a pilot study of detection, enumeration, and next-generation sequencing in cases and controls.
|
|
Academic Article
|
Cabozantinib in Hepatocellular Carcinoma.
|
|
Academic Article
|
Efficacy and safety of cabozantinib for patients with advanced hepatocellular carcinoma based on albumin-bilirubin grade.
|
|
Academic Article
|
Second-line cabozantinib after sorafenib treatment for advanced hepatocellular carcinoma: a subgroup analysis of the phase 3 CELESTIAL trial.
|
|
Academic Article
|
Checkpoint Inhibitors for the Treatment of Advanced Hepatocellular Carcinoma.
|
|
Academic Article
|
Tumor biology and immune infiltration define primary liver cancer subsets linked to overall survival after immunotherapy.
|
|
Academic Article
|
Plain language summary of the HIMALAYA study: tremelimumab and durvalumab for unresectable hepatocellular carcinoma (liver cancer).
|
|
Academic Article
|
Quality of life assessment of cabozantinib in patients with advanced hepatocellular carcinoma in the CELESTIAL trial.
|
|
Academic Article
|
Outcomes Based on Plasma Biomarkers for the Phase 3 CELESTIAL Trial of Cabozantinib versus Placebo in Advanced Hepatocellular Carcinoma.
|
|
Academic Article
|
Molecular pathogenesis and systemic therapies for hepatocellular carcinoma.
|
|
Academic Article
|
Multidisciplinary management of hepatocellular carcinoma.
|
|
Academic Article
|
Cabozantinib: An evolving therapy for hepatocellular carcinoma.
|
|
Academic Article
|
Cholangiocarcinoma - evolving concepts and therapeutic strategies.
|
|
Academic Article
|
Phase Ib Study of Enzalutamide with or Without Sorafenib in Patients with Advanced Hepatocellular Carcinoma.
|
|
Academic Article
|
Safety and efficacy of cabozantinib for patients with advanced hepatocellular carcinoma who advanced to Child-Pugh B liver function at study week 8: a retrospective analysis of the CELESTIAL randomised controlled trial.
|
|
Academic Article
|
A 46-Year-Old Asian Woman With Liver Mass.
|
|
Academic Article
|
Guidelines Insights: Hepatobiliary Cancers, Version 2.2019.
|
|
Academic Article
|
Hepatobiliary Cancers, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.
|
|
Academic Article
|
Temsirolimus combined with sorafenib in hepatocellular carcinoma: a phase I dose-finding trial with pharmacokinetic and biomarker correlates.
|
|
Academic Article
|
Liver transplantation recipients with nonalcoholic steatohepatitis have lower risk hepatocellular carcinoma.
|
|
Academic Article
|
Cabozantinib in hepatocellular carcinoma: results of a phase 2 placebo-controlled randomized discontinuation study.
|
|
Academic Article
|
Imaging Hepatocellular Carcinoma With 68Ga-Citrate PET: First Clinical Experience.
|
|
Academic Article
|
NCCN Guidelines? Insights: Biliary Tract Cancers, Version 2.2023.
|
|
Academic Article
|
90Y glass microspheres for the treatment of unresectable metastatic liver disease from chemotherapy-refractory gastrointestinal cancers: a pilot study.
|
|
Academic Article
|
Radioembolization with 90Y glass microspheres for the treatment of unresectable metastatic liver disease from chemotherapy-refractory gastrointestinal cancers: final report of a prospective pilot study.
|
|
Academic Article
|
Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline.
|
|
Academic Article
|
"And what other medications are you taking?".
|
|
Academic Article
|
Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline Update.
|
|
Academic Article
|
A Phase 2 Study of Galunisertib (TGF-?1 Receptor Type I Inhibitor) and Sorafenib in Patients With Advanced Hepatocellular Carcinoma.
|
|
Academic Article
|
Hepatobiliary cancers, version 2.2014.
|
|
Academic Article
|
Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma.
|
|
Academic Article
|
A single H/ACA small nucleolar RNA mediates tumor suppression downstream of oncogenic RAS.
|